L1210 leukemia i.v. implanted as a model for testing short-chain nitrosourea analogs

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Oncology

Background:

• Nitrosoureas are a class of chemotherapy drugs.
• L1210 mouse leukemia is a common model for evaluating anti-cancer drugs.
• Intravenous (i.v.) administration may offer advantages for tumor inoculation and drug delivery.

Purpose of the Study:

• To synthesize and evaluate novel 2-chloroethyl-nitrosourea and 2-fluoroethyl-nitrosourea compounds.
• To compare the cytostatic activity of these new compounds against L1210 mouse leukemia with existing nitrosoureas.
• To investigate the biodistribution of tumor cells following i.v. injection.

Main Methods:

• Synthesis of 11 2-chloroethyl-nitrosoureas and 1 2-fluoroethyl-nitrosourea.
• Cytostatic activity testing using the L1210 mouse leukemia model.
• Bio-assay to determine tumor cell distribution in various organs after i.v. injection.

Main Results:

• Intravenous tumor inoculation resulted in 10 to 100 times higher tumor cell counts in organs compared to intraperitoneal implantation.
• Ten of the newly synthesized nitrosourea compounds demonstrated significant cytostatic activity, leading to cures in the L1210 mouse leukemia model.
• Five of the novel compounds exhibited superior efficacy compared to carmustine (BCNU), a widely used nitrosourea drug.

Conclusions:

• Novel nitrosourea derivatives show potent anti-leukemic activity in a preclinical mouse model.
• The i.v. route facilitates wider tumor cell dissemination, relevant for evaluating systemic therapies.
• Several synthesized compounds represent promising candidates for further development as anti-cancer agents, potentially offering improved efficacy over BCNU.